Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Thursday 29 November, 2018

GlaxoSmithKline PLC

GSK - Update on Review of Horlicks

RNS Number : 9286I
GlaxoSmithKline PLC
29 November 2018


Issued: 29 November 2018, London UK - LSE Announcement


GSK - Update on Strategic Review of Horlicks  





As disclosed previously, in March 2018, GlaxoSmithKline Plc ("GSK") announced a strategic review of Horlicks and its other consumer healthcare nutrition products. The majority of Horlicks and other GSK nutrition products sales are generated in India by GlaxoSmithKline Consumer Healthcare Limited (the "GSKCH"). In response to recent press speculation, GSK confirms that consideration is being given to a potential transaction that includes a merger of GSKCH. There can be no assurance that a transaction will result from the review process or the evaluation of this option nor has any decision on the matter been made by the Company.




GSK enquiries:

UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502


US Media enquiries:

Sarah Spencer

+1 267 253 7349


(North Carolina)

Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194


James Dodwell

+44 (0) 20 8047 2406


Danielle Smith

+44 (0) 20 8047 7562


Jeff McLaughlin

+1 215 751 7002





Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.



Registered in England & Wales:

No. 3888792


Registered Office:

980 Great West Road

Brentford, Middlesex



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t